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Objectives. This summary evaluates the outcomes of orthotopic liver transplantation (OLT) of HIV-positive patients in Germany.
Methods. Retrospective chart analysis of HIV-positive patients, who had been liver-transplanted in Germany between July 1997
and July 2011. Results. 38 transplantations were performed in 32 patients at 9 German transplant centres. The reasons for OLT
were end-stage liver disease (ESLD) and/or liver failure due to hepatitis C (HCV) (n = 19), hepatitis B (HBV) (n = 10), multiple
viral infections of the liver (n = 2) and Budd-Chiari-Syndrome. In July 2011 19/32 (60%) of the transplanted patients were
still alive with a median survival of 61 months (IQR (interquartile range): 41–86 months). 6 patients had died in the early post-
transplantation period from septicaemia (n = 4), primary graft dysfunction (n = 1), and intrathoracal hemorrhage (n = 1). Later
on 7 patients had died from septicaemia (n = 2), delayed graft failure (n = 2), recurrent HCC (n = 2), and renal failure (n = 1).
Recurrent HBV infection was eﬃciently prevented in 11/12 patients; HCV reinfection occurred in all patients and contributed
considerably to the overall mortality. Conclusions. Overall OLT is a feasible approach in HIV-infected patients with acceptable
survival rates in Germany. Reinfection with HCV still remains a major clinical challenge in HIV/HCV coinfection after OLT.
1.Introduction
The introduction of highly active antiretroviral therapy
(HAART) in 1996 has enabled the control of human-
immunodeﬁciency-virus (HIV)-infection in most patients
andresultedinamarkeddecreaseinopportunisticinfections
and an increase in life expectancy [1, 2]. Since HIV has
now become a chronic disease, comorbidities are of increas-
ing clinical importance. Among HIV-infected patients in
Germany HCV coinfection rates range between 10 and 15%
[3], and the prevalence of HBV surface antigen (HBs-Ag)
is estimated to be 10% [4]. Thus end-stage liver disease
has become a prominent problem in these patients, and
the demand for liver transplantation is increasing. Indeed,
liver-associated mortality of HIV-coinfected subjects with
viral hepatitis has become a leading cause of death in many
countries [5, 6]. Despite recent advances in the treatment of
chronic hepatitis B and hepatitis C, OLT remains the last2 AIDS Research and Treatment
resort for patients with decompensated liver cirrhosis.
According to the 1993 consensus conference on indications
for liver transplantation HIV infection was initially con-
sidered a contraindication, but the advent of HAART in
1996 improved prognosis of HIV-infected patients and has
encouraged many transplant centers to accept selected HIV-
positive candidates, and meanwhile more than 300 liver
transplantations have been reported worldwide with overall
promising outcomes [7–10].
Here we evaluate the outcomes of all liver transplanta-
tions in HIV-positive patients receiving a liver graft between
July 1997 and July 2011 in Germany.
2. Patientsand Methods
After contacting all German transplant centers which had
oﬀered transplantation to HIV-infected patients, we con-
ducted a retrospective observational cohort study.
A standardized questionnaire comprising general demo-
graphic data (gender, age, and body weight), characteristics
of HIV infection (date of diagnosis, CDC stadium, trans-
mission risk factor, CD4 cell count, quantitative HIV-RNA,
use of HAART), and details of liver disease and OLT (type
of diagnosis, biochemical and clinical signs of liver disease,
complications of OLT) was used for collecting data. The data
were analyzed for 4 diﬀerent time points: at the listing for
OLT, at OLT itself, at (re)initiation of HAART after OLT and
ﬁnally at the last available followup.
Thedatawereevaluatedwithregardtocriteriaforpatient
selection, organ dysfunction, and reasons for OLT and
mortality. The Kaplan-Meier method was used to estimate
the survival function. In addition to survival, causes of death
as well as therapy and recurrence of viral hepatitis were
analyzed. The model for end-stage liver disease (MELD)
score [11], which has been used for organ allocation since
December 2006, was calculated as a marker of liver disease
severity.
3. Results
3.1. Criteria for Patient Selection. All centers reported that
criteria for selecting a candidate for OLT were CD4 counts
≥100cells/µL and HIV-RNA below the limit of detection
or at least a reasonable option for eﬃcient HAART if
antiviral medications were to be started in the posttransplant
period. Indeed, ﬁve patients each had a history of an
opportunistic infection prior to OLT: varicella-zoster virus
infection, esophageal candidiasis, pneumocystis pneumonia,
CMV disease, and tuberculosis; the 4 patients with AIDS-
deﬁning complications were on eﬀective HAART prior to
listing for liver transplantation, and opportunistic diseases
had been successfully controlled before OLT. An AIDS-
deﬁning event prior to listing of OLT was not considered
as an exclusion criterion unless they were chronic diseases
with limited treatment options (e.g., progressive multi-
focal leukoencephalopathy, chronic cryptosporidiosis, and
multidrug-resistant systemic fungal infections).
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Figure 1: Thirty-eightliver transplantationsperformed on32HIV-
infected patients from July 1997–July 2011 in Germany.
All centers agreed that contraindications for transplan-
tation were ongoing alcohol or drug abuse, advanced HCC
metastases in other organs, other concurrent malignant
disease, advanced cardiopulmonary disease, and age > 65
years.
3.2. Characterization of Transplanted Patients. In total 38
transplantationswereperformedin32HIV-positivepatients,
including 2 re-retransplantations and 2 retransplantations.
Ten patients were transplanted in Bonn, 8 in Essen, 3
in Heidelberg, 3 each in Hamburg and Frankfurt, 2 in
Mainz, and one patient each in T¨ ubingen, Hannover, and
Regensburg.
Overall, 31 male and 1 female patients were treated
by liver transplantation during the observation period, one
of whom had also received a kidney graft due to acute
kidney failure on a preexisting chronic kidney disease. The
median age at transplantation was 47 years (IQR, 37–52),
and patients had a median duration of HIV infection of
16 years (IQR, 12–19) (Table 1). The annual rates of liver
transplantation in the German HIV-positive patients are
shown in Figure 1. Details on immunosuppression were
available only from 5 centers (25 patients). Also in 2 HIV-
positive patients with recurrent hepatitis C, data concerning
antiviral HCV therapy were missing.
Transplantation was done under the high urgency code
for 4 patients with acute liver failure due to a hepatitis B:
these received an organ between 1 and 7 days after listing.
One patient was listed urgently for combined kidney and
liver transplantation to treat acute liver failure after ﬂu-
conazole and coexisting insuﬃciency. This patient received
a liver and kidney graft 44 days after listing. In elective
patients livers were allocated according to waiting time until
December 2006, when the MELD system was introduced.
Median waiting time was 145 days for elective patients
listed in the pre-MELD era and 120 days for patients listed
after December 2006. Further patient characteristics are
summarized in Tables 1 and 2.
Concerning HIV infection, two of the patients with
fulminant hepatitis B were incidentally diagnosed to be
HIV-positive during workup for OLT. One patient with
chronic hepatitis B was discovered to be HIV-positive afterAIDS Research and Treatment 3
Table 1: Demographic data and clinical characteristics of all 32
HIV-positive patients who received a liver graft between July 1997
and July 2011 in Germany.
Age (median (IQR)) 47 [37–52]
Gender (male/female) 31:01
Risk of HIV infection (n(%))(a)
Blood products 13/30 (43%)
Homo/heterosexual 9/30 (30%)
Intravenous drug abuse 6/30 (20%)
Unknown 2/30 (7%)
CD4 count (Cell/µL) (median (IQR))(a) 266/µL [197–370]
CD4 count >200 (n (%)) 22/31 (71%)
CD4 count >100 (n (%)) 7/31 (23%)
CD4 count <100 (n (%)) 2/31 (6%)
Plasma HIV RNA (<50 copies/mL) (n
(%))(a) 16/31 (52%)
Antiretroviral therapy before OLT (n
(%))(a)
PI-based regimen
17/31 (55%)
Efavirenz-based regimen 6/31 (19%)
Efavirenz and Kaletra 1/31 (3%)
3N R T I 4 / 3 1( 1 3 % )
No ART 3/31 (10%)
Antiretroviral therapy after OLT (n
(%))(a)
PI-based regimen
17/30 (57%)
Efavirenz-based regimen 3/30 (10%)
Efavirenz and Kaletra 1/30 (3%)
3N R T I 6 / 3 0( 2 0 % )
No ART 3/30 (10%)
Reasons for OLT
HCV coinfection 19 (1 ETOH, 5 HCC)
HCV+HBV coinfection 1 (1 HCC)
HBV coinfection 10 (1 ETOH, 1 HCC)
HBV+HCV+HDV coinfection 1
Budd-Chiari syndrome 1
Child-Pugh score and Meld score at the
day of OLT(a)
Child-Pugh class A (n (%))
5/30 (17%)
Child-Pugh class B (n (%)) 7/30 (23%)
Child-Pugh class C (n (%)) 18/30 (60%)
Meld (median (IQR))(a) 17 [13–29]
Ascites prior to OLT(a) 14/29 (48%)
Hepatic encephalopathy prior to OLT(a) 8/29 (28%)
Variceal hemorrhage prior to OLT(a) 4/29 (14%)
PI: protease inhibitor; NRTI: nucleoside/nucleotide reverse transcriptase
inhibitor; ETOH: alcoholic cirrhosis; HCC: hepatocellular carcinoma; HCV:
hepatitis C; HBV: hepatitis B; HDV: hepatitis D.
(a)Information was not available for all patients.
OLT. In 29 patients HIV-infection had been known prior
to evaluation for liver transplantation. In the 3 remaining
patients the temporal relationship between the diagnosis of
Table 2: HCC in liver-transplanted HIV-infected patients.
Viral
hepatitis Outcome HCC ﬁndings
HCV Death 1 HCC focus§
HCV Living 2 HCC foci§ (max. 1.7cm)
HCV Living 3 HCC foci (max 0.7cm)
HBV Living Multifocal HCC (max.
2cm)
HCV Death, HCC relapse Multifocal HCC
HCV Death, HCC relapse n.d.
HCV/HBV Living 1 HCC focus§ (max 1.2cm)
HCC: hepatocellular carcinoma; HCV: hepatitis C; HBV: hepatitis B.
n.d.: no data. §HCC was found incidentally on explant pathology.
HIV-infection and evaluation for transplantation was not
reported.
At the time of transplantation all patients had CD4 T-
cell counts above ≥100/µL; 71% of the patients had CD4 T-
cell counts ≥200 cell/µL; HIV-RNA was below the limit of
detection of 50 copies/ml in 16 patients (52%). The median
MELD score at the day of transplantation was 17 (IQR, 13–
29) (N = 27). Prior to transplantation ascites had occurred
in 14 patients, variceal hemorrhage in 4 patients, and hepatic
encephalopathy in 8 patients.
3.3. Complications after OLT. Nineteen of the 32 trans-
planted patients in Germany are still alive in 2011 after a
median followup of 61 months (IQR, 41–86) giving rise to
an overall mortality of 41%.
In 5 centres where more than 2 patients were trans-
planted, mortality varied between 20% and 63%. Causes of
death are summarized in Table 3.
Six patients died in the early posttransplantation period
during the ﬁrst 3 months after liver transplantation.
Seven patients died 8, 10, 13, 25, 31, 56, and 93 months
after liver transplantation, respectively.
One patient had received a graft from an HCV-positive
donor. This patient suﬀered recurrent hepatitis C rapidly
progressing to cirrhosis and received a second graft 4.5
years after the initial transplantation; he had primary graft
dysfunction after retransplantation and died from sepsis 3
months after receiving a second liver graft. Retransplanta-
tion, owing to primary graft nonfunction and ischemic type
biliary lesions (ITBLs), had been successfully performed in
one patient each. Finally, re-retransplantation was successful
inaHIV/HBV-coinfectedpatientwhodevelopeddecompen-
sated secondary biliary cirrhosis 13 years after his second
transplantation.
Graft rejection was observed in 10 patients, which was
lethal in one patient but was successfully treated with
high-dose prednisone in the remaining 8 patients. Another
patient suﬀered tonic clonic convulsions requiring transient
reintubation during postoperative recovery and ultimately
developed left-sided hemiparesis.
CMV viremia was detected in 5 patients and preemp-
tively treated with intravenous ganciclovir. One patient4 AIDS Research and Treatment
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developed cutaneous Kaposi’s sarcoma 126 days after OLT.
Reduction of immunosuppression led to a transient regres-
sion. However, Kaposi’s sarcoma in combination with mul-
ticentric Castleman’s disease reoccurred 18 months later
although CD4 counts were above 350 CD4-cells/µL at this
time. This patient was successfully rescued by liposomal
doxorubicin, and he is still alive after 96 months. In another
patient secondary liver failure occurred after chemotherapy
for Hodgkin’s disease 17 months after OLT.
3.4. HAART and Immunosuppression. Reinitiation of HA-
ART was delayed for a median of 16 days (IQR, 2–31)
after OLT in 22/29 patients. Five patients received HAART
continuously. Three patients did not receive HAART after
OLT due to poor liver function. They died early after
22, 24, and 57 days, respectively. In one patient HAART
was initiated after 21 months. This patient spontaneously
showed persistently low HIV-RNA after OLT and high CD4
counts above the thresholds for starting HIV therapy at that
time; he recently was re-retransplanted 13 years after his
second transplantation (see Section 3.3). In two patients
data on antiretroviral management were not available.
Details of antiretroviral therapy are summarized in Table
1. Azidothymidine (AZT) was used in HAART in 6 and 4
patients before and after OLT, respectively. Also stavudine
(D4T) had been given before and after OLT in 6 and 4
patients, respectively. Two of the patients had died from
causes unrelated to this drug (patients 2 and 6 in Table 3).
In the other two patients D4T was changed to PIs later on.
Concerning immunosuppression detailed information
was provided from 5 centers covering 25 patients. Nineteen
patients received cyclosporine A (CyA) in addition to
prednisone. In 3 patients calcineurin-inhibitor-associated
nephrotoxicity was observed, and patients were then con-
tinued on mycophenolate mofetil (MMF) and reduced CyA
doses. Three received tacrolimus (TAC) in combination with
MMF. In 4 patients immunosuppression had been started
with CyA and was switched to TAC later on.
3.5. Recurrence of Viral Hepatitis. Mortality after OLT was
20% (2/10) in HIV/HBV-coinfected patients and 47% (9/19)
in HIV/HCV-coinfected patients. Survival in HIV/HCV- and
HIV/HBV-coinfected after liver transplantation is summa-
rizedinFigure 2illustratinga58%and80%estimated5-year
Kaplan Meier survival, respectively.
HBs hyperimmunoglobulin and/or HBV-active antire-
troviral therapy prevented recurrence of hepatitis B in all but
one patient. This patient had received tenofovir (TDV) and
lamivudine (3TC) without HBs-hyperimmunoglobulin and
developed low-level HBV viremia 1 year after OLT. Details
of HBV prophylaxis with HBs-hyperimmunoglobulin in
combination with nucleoside or nucleotide analogues are
shown in Table 4.
19 HIV-positive patients were transplanted for chronic
hepatitis C. One patient each had HCV/HBV/HDV and
HCV/HBV coinfection (Table 1). HCV reinfection occurred
in all 21 HIV-HCV coinfected patients after OLT. Of
note, one patient spontaneously cleared his acute recurrent
Table 4: Recurrence and prevention of hepatitis B in HIV-positive
patients after OLT.
Viral hepatitis HBV therapy HBV virus
HBV 3TC, HBs-Ig HBsAg negative
HBV 3TC, HBs-Ig HBsAg negative
HBV 3TC, HBs-Ig HBsAg negative
HBV TDF, HBs-Ig HBsAg negative
HBV TDF, HBs-Ig HBsAg negative
HBV 3TC HBsAg negative
HBV/HCV/HDV 3TC HBsAg negative
HBV 3TC, entecavir HBsAg negative
HBV TDF, 3TC low viremia
HBV TDF HBsAg negative
HBV/HCV TDF, HBs-Ig HBsAg negative
HBV 3TC HBsAg negative
3TC: lamivudine, TDF: tenofovir, HBs-Ig: HBs hyperimmunoglobulin,
HCV: hepatitis C virus, HBV: hepatitis B virus, HDV: hepatitis D virus.
hepatitis C in the immediate postoperative period under
HAART.
HCV genotypes were available in 14 patients; HCV
genotype 1 and 4 infection was present in 10 (71%) patients
and genotype 2 and 3 in 4 (29%) patients. Details of
recurrent hepatitis C are summarized in Table 5.
12 patients did not receive anti-HCV therapy, 7 of whom
had died (Table 5), while the other 5 patients are still alive
after a median of 36 months (IQR, 28–48).
Therapy with pegylated interferon plus ribavirin (plus
amantadine in 3 patients) was attempted in 7 patients
after a median of 69 days (IQR, 39–107) after OLT. Five
of the 7 patients (72%) achieved a sustained treatment
response (SVR) with negative HCV-RNA 24 weeks after the
completion of HCV therapy, whereas an early treatment
response (EVR; reduction of HCV-RNA of >2l o g1 0a tw e e k
12) was achieved in only 2 of the 7 (28%) patients. The
remaining 2 patients (28%), who had received anti-HCV
therapy, were null responders.
4. Discussion
Liver transplantation of HIV-infected patients is now con-
sidered a reasonable option in the HAART era. Multiple
studies have reported promising results of HAART-treated
HIV-infectedpatientswithmaximallysuppressedviralloads,
stable CD4 counts, and no signiﬁcant increase in oppor-
tunistic infections after OLT [7, 12–15]. Here, we summarize
the results of liver transplantation in HIV-positive patients
from Germany. The overall mortality of liver-transplanted
HIV-positive patients in Germany was 41% (13/32). These
results are comparable to the 36% mortality rate reported
by Spanish transplant centres [8]; the mortality rate in HIV-
infected patients transplanted in the UK was 30% [9]. Thus,
outcomes of liver transplantation in Germany also support
the concept that liver transplantation should be oﬀered to
selected HIV-positive patients.6 AIDS Research and Treatment
Table 5: Recurrence of hepatitis C in HIV-infected patients and outcome after OLT.
Viral hepatitis HCV genotype HCV therapy Nonresponse Survival, followup
(months)
HCV 2a/2c IFN/RBV/amantadine SVR Living, 114
HCV 3a IFN/RBV SVR Death, 93
HCV 1a IFN/RBV/amantadine EVR/SVR Living, 89
HCV 1a IFN/RBV/amantadine EVR/SVR Living, 82
HCV 1a IFN/RBV SVR Living, 66
HCV/HBV/HDV 1a IFN/RBV Nonresponse Death, 56
HCV 1a/b IFN/RBV Nonresponse Death, 8
HCV n.a. No / Death, 31
HCV 3a No / Death, 25
HCV n.a. No / Death, 13
HCV n.a. No / Death, 10
HCV 1a No / Death, 3
HCV n.a. No / Death, 2
HCV n.a. No / Death,1
HCV n.a. No / Living, 74
HCV 1b n.a. n.a. Living, 32
HCV 1b n.a. n.a. Living, 67
HCV 3a No / Living, 39
HCV/HBV 1 No / Living, 18
HCV 1a No / Living, 44
HCV n.a. No Spontaneous
viral clearance Living, 54
IFN: interferon, RBV: ribavirin, EVR: early virological response, SVR: sustained virological response, HCV: hepatitis C virus, HBV: hepatitis B virus, HDV:
hepatitis D virus.
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Figure 2: Kaplan-Meier survival after liver transplantation. The left Kaplan-Meier plot illustrates survival probabilities stratiﬁed for
HIV/HCV and HIV/HBV coinfection. Two patients with HCV/HBV and HCV/HBV/HDV coinfection had been excluded in this analysis.
The right plot illustrates survival probabilities for all HIV-positive patients after liver transplantation.AIDS Research and Treatment 7
HIV monoinfection or opportunistic infections alone
did not seem to be signiﬁcant risk factors for survival after
transplantation in the German patients. Both, in patients
from Germany and those reported from other countries,
bacterial infections and sepsis had been the leading causes
of mortality after liver transplantation, accounting for about
50% of deaths in the patients from Germany, particularly
early after transplantation. Of note, 10 of the 13 German
patients who had died after liver transplantation also had
HCV/HIV coinfection. Current data indicate that HCV co-
infection in HIV-positive patients is associated with poor
survival after OLT [7–10, 14–16] and that HCV coinfection
has a high rate of severe and opportunistic infections
[17]. The estimated 5-year survival probabilities for 81
Spanish HIV/HCV-coinfected patients were 47.9%, for 16
coinfected patients in the UK, 53%, for patients from France,
51%, and for the HIV/HCV-positive patients in Germany,
58%. [8, 9, 18]. Thus, survival in HIV-positive patients
after liver transplantation was rather similar across the
European countries. In contrast, a US study reported a
signiﬁcantly worse ﬁve-year patient survival rate of 33% in
HCV/HIV-coinfected patients [19], while in a second study
the reported 50% ﬁve-year survival rate matched those of the
European countries [8]. Nevertheless, in a large retrospective
cohort analysis Mindikoglu et al. proposed that HIV/HCV-
coinfected patients had a signiﬁcantly lower 2-year survival
probability after OLT (52%) than HIV-negative patients
with hepatitis C (79%) or HIV-negative patients without
HCV infection (81%). In a smaller group of patients,
however, 3-year survival of HIV/HCV-co-infected patients
after OLT was reported to be similar to patients with
HCV monoinfection [20]. These discrepancies probably
reﬂect diﬀerences in the management of HCV infection and
underline the importance of an aggressive anti-HCV therapy
early after transplantation in HIV/HCV-coinfected patients
due to developing ﬁbrosing cholestatic hepatitis [21].
Treatment for recurrent HCV seems to have a positive
eﬀect on graft survival and mortality [22]. Treatment of hep-
atitis C infection in HIV coinfected patients must be tailored
in an individualized manner to account for the prolonged
time necessary for elimination of HCV, since clearance of
HCV RNA appears to be slower than in HCV-mono-infected
patients [23, 24]. Moreover, Vogel et al. showed that delayed
initiation of HAART after transplantation and slow tapering
of prednisone after stable immunosuppression seem to exert
a positive impact on the course of hepatitis C infection [25].
Ab e n e ﬁ c i a le ﬀect of anti-HCV therapy is also suggested in
ourretrospectivestudy,sinceSVRwasachievedin72%ofthe
HIV/HCV-coinfectedpatientsreceivingHCVtreatmentafter
OLT. This remarkable outcome of anti-HCV therapy may
also reﬂect meticulous selection of suitable patients for liver
transplantation,sincearatherpoorSVRof31%wasreported
for interferon plus ribavirin therapy in a large Spanish
cohortof711HIV/HCV-infectedpatients[26].Nevertheless
HCV coinfection still pivotally contributed to the mortality
of HIV-positive patients after liver transplantation in the
German HIV-positive patients.
Unlike HCV coinfection, HIV-infected patients with
HBV seem to have better outcomes after OLT [27] when
prophylaxis of HBV reinfection of the graft is correctly pro-
vided[12, 27]. This concept is also supported by the German
transplant experience in HIV-positive patients, because only
a single patient had recurrence of HBV infection under
HBV prophylaxis. Of note, survival between HIV/HBV-
coinfected patients and patients with HBV monoinfection
does not seem to diﬀer after liver transplantation [7, 24].
The King’s College Hospital group reported even a survival
rate of 100% at 5 years [28]. The 5-year survival rate for
HIV/HBV-coinfected patients was 80% in the German
patients, and none of the HIV/HBV-coinfected patients
developed clinically relevant HBV-related liver disease after
OLT. Recurrence of HBV infection in the single patient
with hepatitis B recurrence was associated with a regimen
not comprising HBs hyperimmunoglobulin, suggesting that
prophylaxis of HBV recurrence should comprise both HBs
hyperimmunoglobulin and antiviral drugs with anti-HBV
activity [27, 29, 30]. Despite successful prevention of recur-
rent hepatitis B, 50% of the patients on such a combined
regimen had detectable low-level HBV viremia in a study but
nevertheless achieved 85% patient survival over a followup
of 4 years [30].
Drugs given as part of HAART as well as immuno-
suppressive drugs strongly interact with drug-metabolizing
enzymes, for example, the cytochrome P450 system. Thus,
complex interactions between immunosuppressive regimens
and antiretroviral therapy present a particular challenge for
the treating physician; they must consider the optimal time
of HAART initiation, the drug-drug interactions between
HAART and immunosuppressive drugs, as well as control of
posttransplant disease recurrence. Starting HAART imme-
diately after OLT may exert a negative eﬀect on mortality,
especially in HIV/HCV co-infection, because drug-related
livertoxicitymaybeeasilyconfusedwithothercausesofgraft
dysfunction in the early posttransplant period [31]. Also 4 of
the 10 HIV/HCV-coinfected patients in Germany, who had
died, had an early start of HAART in the ﬁrst 4 days after
OLT. The selection of drugs for immunosuppression and
antiretroviral therapy is a further critical factor. In the early
attempts of liver transplantation in HIV-positive patients
with recurrent hepatitis C, dose adjustments of calcineurin
inhibitors were not performed; this may have resulted in
excessive immunosuppression and death within the ﬁrst 2
years after OLT [16].
In selecting drugs for HAART potential hepatotoxicity
must be taken into consideration in order to reduce liver-
associatedmortality[31,32];theapplicationofantiretroviral
agents with low potential for interactions with other drugs,
for example, integrase inhibitors, may reduce posttransplant
hepatotoxicity of HAART [33]. On the other hand the use
of drugs with high hepatotoxic potential such as didanosine
(ddI), stavudine (D4T), or azidothymidine (AZT) should
be avoided [34]. Furthermore, ddI use is contraindicated
in combination with ribavirin because this combination
increases the risk of pancreatitis and mitochondrial toxicity.
None of the German patients had received ddI but 4 patients
had transiently been treated with D4T. Nevertheless D4T
drug toxicity is unlikely to have contributed to the high
mortality in this subgroup, since the two patients who8 AIDS Research and Treatment
succumbed had died either from surgical complications or
hepatotoxic chemotherapy for lymphoma.
5. Conclusions
Despite some regional diﬀerences in the outcome of trans-
planted HIV-infected patients in Germany, the overall mor-
tality does not diﬀer from that of other European countries.
This favorable outcome with acceptable survival rates justi-
ﬁes the strategy to oﬀer liver transplantation to HIV-infected
patients with fulminant hepatic failure and end-stage liver
disease. The outcome of this option may be improved
with better criteria for patient selection and posttransplant
management of recurrent liver disease. Nevertheless, the
care for such patients still requires a meticulous balance of
complex interacting factors such as the choice of HAART,
correct dose adjustments of immunosuppressive drugs, and
the optimal timing of therapy.
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